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Abstract 20 
Objectives The aim of this study was to optimize dexmedetomidine and alfaxalone 21 
dosing, for intramuscular administration with butorphanol, to perform minor surgeries 22 
in cats.  23 
Methods Initially, cats were assigned to one of 5 groups, each composed of 6 animals 24 
and receiving, in addition to 0.3 mg/kg butorphanol IM, one of the following: A: 0.005 25 
mg/kg dexmedetomidine, 2 mg/kg alfaxalone; B: 0.008 mg/kg dexmedetomidine, 1.5 26 
mg/kg alfaxalone; C: 0.012 mg/kg dexmedetomidine, 1 mg/kg alfaxalone; D: 0.005 27 
mg/kg dexmedetomidine, 1 mg/kg alfaxalone; and E: 0.012 mg/kg dexmedetomidine, 2 28 
mg/kg alfaxalone. Thereafter, a modified “direct search” method, conducted in a 29 
stepwise manner, was used to optimize drugs dosing. The quality of anaesthesia was 30 
evaluated on the basis of composite scores (one for anaesthesia and one for recovery), 31 
of Visual Analogue Scales, and of propofol requirement to suppress spontaneous 32 
movements. The medians or means of these variables were used to rank the treatments: 33 
“unsatisfactory” and “promising” combinations were identified to calculate, through the 34 
equation first described by Berenbaum in 1990, new dexmedetomidine and alfaxalone 35 
doses to be tested in the next step. At each step, 5 combinations (one new plus the best 36 
previous four) were tested.   37 
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Results None of the tested combinations resulted in adverse effects. Four steps and 120 38 
animals were necessary to identify the optimal drug combination (0.014 mg/kg 39 
dexmedetomidine, 2.5 mg/kg alfaxalone and 0.3 mg/kg butorphanol).  40 
Conclusions and relevance The investigated drug mixture, at the doses found with the 41 
optimization method, is suitable for cats undergoing minor clinical procedures.  42 
 43 
Keywords: alfaxalone, butorphanol, cats, dexmedetomidine, injectable anaesthesia, 44 
optimization method 45 
 46 
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Introduction 56 
In several Swiss veterinary practices, intramuscular injectable anaesthesia is preferred 57 
over intravenous and inhalational techniques for feline patients undergoing minor 58 
clinical procedures. The rationale for this tendency may be the common belief, among 59 
general practitioners, that deep sedation is safer than inhalational anaesthesia. As an 60 
alternative explanation, owing to the uncooperative nature of feline patients, intravenous 61 
catheterization can be challenging in non-sedated cats and this may prevent 62 
veterinarians from attempting physical restraint.  63 
To date, several drug combinations have been investigated for feline intramuscular 64 
anaesthesia. Commonly used protocols often include an alpha2-adrenoreceptor agonist 65 
to produce reliable sedation, an opioid derivative to provide some analgesia, and 66 
ketamine owing to its anaesthetic and analgesic effects.  67 
Among alpha2-adrenoreceptor agonists, dexmedetomidine - the active enantiomer of 68 
racemic medetomidine - has recently been licensed for administration to cats in some 69 
countries and has gained wide popularity in general practice owing to its convenience, 70 
ease of administration and possibility to antagonize its effects. Several investigators 71 
found that dexmedetomidine is a reliable sedative in feline patients and produces dose-72 
dependent analgesia and muscle relaxation with acceptable side effects.1,2 These features 73 
make this compound suitable as sole agent for minor clinical procedures associated with 74 
mild nociceptive stimulation. 75 
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Butorphanol is a synthetic opioid with agonistic activity at ĸ-opioid receptors and 76 
antagonistic effects at µ receptors.3 Because in most countries is not listed among 77 
controlled substances, it is very often preferred over more potent opioid derivatives by 78 
many practitioners in Europe. After intramuscular administration, butorphanol 79 
decreased the thermal nociceptive threshold and produced short lasting and variable 80 
analgesia in cats.4,5 Its combination with dexmedetomidine resulted in greater sedation 81 
and more profound muscle relaxation, but not faster onset of recumbency, than 82 
dexmedetomidine alone in experimental cats.6 83 
Ketamine is a dissociative anaesthetic with high bioavailability and short onset of action 84 
after intramuscular administration.7 Its use has been widely investigated in feline 85 
patients.8-12 However, its addition to dexmedetomidine and butorphanol was found to 86 
prolong the time to recovery.6 87 
As an alternative to ketamine, the inclusion of alfaxalone in alpha2-adrenoreceptor 88 
agonists-opioids combinations may offer some advantages for cats undergoing minor 89 
procedures, namely short duration of the anaesthetic effect, high therapeutic index, and 90 
excellent muscle relaxation.13 Additionally, clinical studies investigating the effects of 91 
subcutaneous alfaxalone prepared in 2-hydroxypropyl-beta cyclodextrin solution seem 92 
to indicate a rapid systemic absorption when routes of administration other than 93 
intravenous injection are used.14,15 94 
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On the basis of the current literature, dexmedetomidine-butorphanol-alfaxalone 95 
intramuscular combination can be considered a promising anaesthetic technique for cats 96 
undergoing minor clinical procedures. The optimal dose combination of these three 97 
drugs is unknown and unlikely to be identified by randomized controlled study, due to 98 
the numbers of animals required for all possible combinations to be investigated. For 99 
this reason, we applied a modified “direct search” model,16 an innovative optimization 100 
method based on a mathematical algorithm, whose main advantage is that a limited 101 
number of dose combinations  - and therefore a limited number of patients – require 102 
investigation.  103 
The aim of the current study was to optimize the doses of intramuscular 104 
dexmedetomidine, butorphanol and alfaxalone, in terms of reliability and rapid onset of 105 
anaesthesia and absence of peri-anaesthetic complications, in domestic cats undergoing 106 
minor surgical procedures.  107 
 108 
Materials and methods 109 
Study design and ethical approval 110 
This study was designed as an investigator-blind, randomized, prospective clinical trial, 111 
and performed with permission of the local Ethics Committee for Animal 112 
Experimentation (Canton of Berne, Switzerland, license number: 22197) and written 113 
informed owner consent. 114 
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Animals 115 
One hundred and twenty client-owned adult cats admitted to the Veterinary Teaching 116 
Hospital of the University of Berne from January 2013 to January 2015 for minor 117 
surgical procedures (wound curettage followed by bandage/wound dressing change, or 118 
control radiographic exam followed by external pin removal) were enrolled in the study.  119 
Food, but not water was withheld for 12 hours prior to anaesthesia. Cats underwent a 120 
routine pre-anaesthetic physical examination in order to assess the health status. In 121 
cooperative animals, in which venipuncture and blood sampling could be performed 122 
without sedation, basic blood parameters (hematocrit, total proteins and electrolytes and 123 
serum creatinine levels) were also assessed. Exclusion criteria were pregnancy, systemic 124 
diseases, impaired cardiovascular function, elderly (more than 8 years) and ASA risk 125 
classification grade greater than II. 126 
The animals were randomly assigned to one of five treatment groups. A manual 127 
randomization technique was used (drawing group assignment from an opaque 128 
envelope).  129 
Treatment groups 130 
Cats were injected intramuscularly (IM) with a mixture of dexmedetomidine 131 
(Dexdomitor; Pfizer), alfaxalone (Alfaxan; Vétoquinol) and butorphanol (Morphasol; 132 
Graeub), mixed in one syringe, at one of the following dose-combinations:  133 
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• GROUP A: 0.005 mg/kg dexmedetomidine, 2 mg/kg alfaxalone and 0.3 mg/kg 134 
butorphanol. 135 
• GROUP B: 0.008 mg/kg dexmedetomidine, 1.5 mg/kg alfaxalone and 0.3 mg/kg 136 
butorphanol. 137 
• GROUP C: 0.012 mg/kg dexmedetomidine, 1 mg/kg alfaxalone and 0.3 mg/kg 138 
butorphanol. 139 
• GROUP D: 0.005 mg/kg dexmedetomidine, 1 mg/kg alfaxalone and 0.3 mg/kg 140 
butorphanol. 141 
• GROUP E: 0.012 mg/kg dexmedetomidine, 2 mg/kg alfaxalone and 0.3 mg/kg 142 
butorphanol. 143 
Each treatment group was composed of 6 cats. The rationale for choosing this number is 144 
explained in the Appendix (Supplementary file). The drugs doses for groups A-E were 145 
selected on the basis of the following criteria: clinical experience of the study’s 146 
designer, existing literature and manufacturers’ recommendations for the species. In 147 
order to avoid iatrogenic muscular lesions, the volume of injectate exceeding 1 ml was 148 
equally divided into two injection sites.  149 
Anaesthetic Procedure 150 
Prior to anaesthesia, baseline values for heart rate (HR), respiratory rate (RR) and rectal 151 
body temperature were recorded. To evaluate the baseline temperament and behavior, 152 
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each cat was assigned to one of three categories: tranquil and quiet, stressed or scared, 153 
and aggressive.  154 
The time to anaesthesia, defined as the minutes elapsing from injection to lateral 155 
recumbency, was recorded. 156 
The occurrence of undesired effects after IM injection, namely vomitus, 157 
hypersalivation, respiratory depression and/or increased muscular tone, was noted. A 158 
score ranging from 0 to 4 (Undesired Effects Score) was assigned to each cat, with 0 159 
being “none of the listed side effects was observed” and 4 being “all the listed side 160 
effects were observed”. 161 
Ten minutes after IM injection, a catheter was placed into the right or left cephalic vein, 162 
or in a peripheral vein of one hind limb if judged more appropriate with respect to the 163 
clinical procedure.  164 
The observer evaluated the degree of reaction to IV catheter placement by assigning a 165 
score, ranging from 0 to 4, with 0 being “no reaction”, 1 “mild reaction” (attempts to 166 
withdraw the limb), 2 “moderate reaction” (vocalization and and/or hissing, movements, 167 
one person needed for physical restraint) and 3 “aggressive reaction” (vocalization 168 
and/or hissing, attempts to bite, two people required for adequate physical restraint). 169 
A score ranging from 0 to 5 (Composite Anaesthesia Score), as described by Biermann 170 
and colleagues,11 was assigned every 5 minutes until completion of the clinical 171 
procedures. The latter were started as soon as the cats became laterally recumbent.  172 
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During anaesthesia, the cats were instrumented with a pulse-oximeter (Microcap plus; 173 
Oridion), an electrocardiograph (Schiller AT-4; Medical Device Depot) and a Doppler 174 
(Model 811B; Parks Medical Electronics) for non-invasive arterial blood pressure 175 
measurement. The respiratory rate was determined by visual examination of the thorax. 176 
Arterial oxygen saturation, HR, RR and systolic arterial blood pressure (SAP) were 177 
manually recorded every 5 minutes.   178 
The depth of anaesthesia was assessed on the basis of commonly used clinical 179 
descriptors (presence or absence of corneal and palpebral reflexes and degree of 180 
muscular relaxation).  181 
If major movements, defined as flexion/extension of the limbs and/or of the neck, 182 
and/or lifting of the head, were observed during the surgical procedure, propofol 183 
(Propofol 1%; Fresenius Kabi) was administered IV in steps of 1.5 mg/kg. The number 184 
of propofol boli given to each cat, as well as the time of administration, was recorded. 185 
All cats received oxygen supplementation by mask with the flow rate set to deliver 2 186 
L/min, and a balanced crystalloids’ solution (Ringer-Lactat; Baxter) was administered 187 
intravenously (IV) at the rate of 5 ml/kg/h.  188 
In the event of bradycardia (HR < 100 bpm) with normo- or hypotension (SAP < 100 189 
mmHg) and with or without ventricular escape rhythm, glycopyrrolate (Robinul; 190 
Sintetica SA), 0.01 mg/kg, was given IV. In the event of moderate sinus bradycardia 191 
(HR 99-70 bpm) accompanied by hypertension (SAP > 150 mmHg), no anticholinergic 192 
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was given and the rhythm was watched closely to detect any change from the baseline. 193 
Finally, if severe bradycardia (HR < 70 bpm), or moderate bradycardia accompanied by 194 
hypertension and ventricular escape rhythm, were observed, atipamezole (Antisedan; 195 
Provet) was administered IM at five times the dexmedetomidine dose. The duration of 196 
the clinical procedure was recorded. At the end of the procedure, a 10 cm Visual 197 
Analogue Scale (VAS), with 0 being labeled as worst possible and 10 as best possible, 198 
was used for an overall, subjective evaluation of the quality of anaesthesia. Thereafter, 199 
unless it had been necessary to antagonize the dexmedetomidine before the completion 200 
of the procedure, the cats were injected with IM atipamezole. The time to recovery, 201 
defined as the minutes elapsed from atipamezole injection to active interaction, was 202 
recorded. The rectal body temperature was measured at the end of anaesthesia. 203 
The quality of recovery was assessed by using a Composite Recovery Score, ranging 204 
from 0 to 14 and based on the following descriptors: comfort, coordination, 205 
vocalization, movement during sternal recumbency, locomotor activity and scratching 206 
and grooming, as described by Biermann and others.11 Additionally, a 10 cm VAS, with 207 
0 labeled as worst possible recovery and 10 labeled as best possible recovery, was used.  208 
All the assessments were performed by the same anaesthetist (C.A.), who also injected 209 
the cats and was blind to the treatment. 210 
Optimization Procedure 211 
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The optimization procedure used in this study is a modification of the “direct search” 212 
method as described by Berenbaum and colleagues17 and applied by Sveticic in a 213 
clinical trial involving human patients.16 A detailed description of the methods and of 214 
the equations used is provided in the Appendix (Supplementary file).  215 
The optimization of the drug combination was conducted in a stepwise manner, and the 216 
treatment groups tested at each step were defined as a complex. The initial 5 drugs 217 
combinations tested composed the complex number 1. Within each complex, the best 218 
treatment groups in terms of quality of anaesthesia (greatest median Composite 219 
Anaesthesia Scores, mean VAS Anaesthesia scores and VAS Recovery scores, and 220 
lowest medians of number of propofol boli and Composite Recovery Scores) and 221 
minimal side effects (lowest median Undesired Effects Scores) were identified. These 222 
groups were defined “promising groups”, whereas the remaining ones were classified as 223 
“unsatisfactory groups”. The new complex, to be tested in other 30 cats (6 per each 224 
group), was composed of four of the previously tested treatments (all but the worst one) 225 
plus a fifth one, generated by applying a mathematical model on the basis of the results 226 
of the previous step (Appendix). Data obtained from complex 2 were analyzed as 227 
previously described and used to generate a new complex until an optimal drug doses 228 
combination was found. For alfaxalone, the maximal dose to be used was fixed at 2.5 229 
mg/kg. 230 
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The optimization procedure was considered completed when the scores obtained from 231 
the new drug combination were not better of those of the previously tested treatments, 232 
and when these results were consistent for three consecutive steps. The dose searching 233 
method was to conclude also in case the mathematical model generated a drug 234 
combination which had already been tested in at least one of the previous steps.   235 
Statistics 236 
Commercially available software (NCSS-2007; NCSS and SigmaStat and SigmaPlot 12; 237 
Systat Software Inc.) were used. Normality of data was tested with the Shapiro-Wilk 238 
tests. Descriptive statistics was used for comparison of treatment groups with respect to 239 
the following variables: Composite Anaesthesia Score, VAS Anaesthesia and Recovery 240 
scores, Composite Recovery Scores, medians of number of propofol boli, and Undesired 241 
Effects Scores. The cardiorespiratory variables (HR, RR and SAP) were analyzed with 242 
repeated measures ANOVA, followed by either the Bonferroni or the Tukey-Kramer 243 
multiple comparison test. The duration of the clinical procedure, the time to anaesthesia 244 
and the time to recovery were analyzed with the Kruskal-Wallis one way ANOVA on 245 
ranks, followed by the Dunn’s test. One way ANOVA on ranks was used to compare 246 
the baseline rectal body temperatures of each group with the values measured at 247 
recovery. The Chi-Square test was used to compare the distribution of the two clinical 248 
procedures between treatment groups.  249 
P values < 0.05 and Z values > 1.96 were considered statistically significant. 250 
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 251 
Results  252 
Data for body weight, age and rectal body temperature were normally distributed.  253 
Four complexes, 120 cats and 8 groups, 5 of which included in complex 1 and three new 254 
ones (N1, N2 and N3; Table 1), were necessary to establish the optimal drug 255 
combination, which was 0.014 mg/kg of dexmedetomidine, 2.5 mg/kg of alfaxalone and 256 
0.3 mg/kg of butorphanol.  257 
The optimization procedure concluded after completion of data collection for complex 258 
4, as the fourth new treatment group obtained through the mathematical model was the 259 
same as N2, which had been previously tested.  260 
The cats had a body weight of 4.2 (± 0.8) kg, were aged 4.4 (± 1.6) years and were 61 261 
males (55 of which castrated) and 59 females (all of which spayed). The 8 treatment 262 
groups did not differ with respect to type of clinical procedure (P = 0.66; Table 2), 263 
duration of the latter (P = 0.17; Figure 1), time to anaesthesia (P = 0.79; Table 3) and 264 
time to recovery (P = 0.29; Table 3). Hypertension and bradycardia were observed in 265 
the 11% and 25% of the cats, respectively. However, any statistically significant 266 
difference in HR (P = 0.76), RR (P = 0.32), SAP (P = 0.35) and rectal body temperature 267 
(P = 1.2) was detected, neither between treatments nor between time points (Figure 2, 3 268 
and 4).  269 
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All 8 drug combinations resulted in a degree of unresponsiveness sufficient to allow for 270 
intravenous catheterization ten minutes after injection, so that in all cats physical 271 
restraint was unnecessary. None of the cats required administration of glycopyrrolate or 272 
atipamezole before the end of the clinical procedure. None of the tested treatments 273 
resulted in clinically relevant side effects and anaesthesia and recovery were uneventful 274 
for all the cats enrolled in the study. The medians or means of VAS Anaesthesia, 275 
Composite Anaesthesia Score, number of propofol boli, Undesired Effects Score, VAS 276 
Recovery, and Composite Recovery Score, are summarized in Table 4.   277 
 278 
Table 1 Doses for intramuscular alfaxalone (A), dexmedetomidine (D) and butorphanol 279 
(B), expressed in mg/kg, for 8 treatment groups  280 
GROUP A D B 
A 2 0.005 0.3 
B 1.5 0.008 0.3 
C 1 0.012 0.3 
D 1 0.005 0.3 
E 2 0.012 0.3 
N1 2.5 0.009 0.3 
N2 2.5 0.014 0.3 
N3 2.5 0.010 0.3 
 281 
 282 
Table 2 Number of cats per group with one of three types of baseline temperament, undergoing 283 
one of two types of minor surgical procedures 284 
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  PROCEDURE   TEMPERAMENT 
GROUP WC (n) RX (n) TQ (n) SS (n) A(n) 
A (n = 18) 8 10 5 8 5 
B (n = 6) 2 4 2 3 1 
C (n = 24) 12 12 5 13 6 
D (n = 12) 8 4 1 8 3 
E (n = 24) 13 11 8 10 6 
N1 (n = 18) 10 8 8 5 5 
N2 (n = 12) 8 4 3 8 1 
N3 (n = 6) 4 2 2 3 1 
TOTAL (120) 65 55 34 58 28 
 285 
WC = wound curettage followed by bandage/dressing change; RX = control RX followed by 286 
external pins removal; TC = tranquil and quiet; SS = stressed or scared; A = aggressive.  287 
 288 
Table 3 Medians and ranges [max-min] of time to anaesthesia, defined as the minutes 289 
elapsed from IM injection to lateral recumbency, and time to recovery, defined as the 290 
minutes elapsed from atipamezole IM injection to active interaction 291 
GROUP Time to anaesthesia  Time to recovery  
A 6.5 [2-20] 12 [5-35] 
B 5 [5-13] 11.5 [2-16] 
C 5 [1-20] 7 [1-47] 
D 7.5 [2-12] 15 [5-30] 
E 5 [1-20] 7 [2-75] 
N1 5 [2-20] 18.5 [5-40] 
N2 5 [1-11] 9.5 [2-35] 
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N3 4 [2-8] 15.5 [2-32] 
 292 
Table 4 Variables for complex 1, 2, 3 and 4, presented as either means‡ or medians*. 293 
The worst treatment group (to be excluded from the optimization process) is colored in 294 
red, while the best final treatments are in bold characters. 295 
Complex Group VAS A‡ CAS* PropB * UES‡ VAS R* CRS* Final score 
1 A 8.78 5 0.5 0 7.80 2.5 P 
1 B 4.28 3.50 3 0 6.50 3 U 
1 C 7.75 4.5 1.5 0 6.10 3 U 
1 D 6.15 4 1 0 7.50 2 U 
1 E 9.57 5 0 0 8.53 1 P 
2 A 9.00 4.5 1 0 7.90 2 U 
2 C 7.80 4.5 1 0 8.00 2 U 
2 D 7.55 4.5 2 0 7.10 2 U 
2 E 9.25 4.5 0 0 9.15 0.5 P 
2 N1 9.50 5 0 0 9.20 0 P 
3 A 8.30 4.5 1 0 7.15 2.5 U 
3 C 8.35 4.75 1 0 8.60 2 U 
3 E 9.45 5 0.5 0 8.3 2 U 
3 N1 9.40 5 0.5 0 9.7 1 P 
3 N2 9.75 5 0 0 9.65 1.5 P 
4 C 7.33 4.5 1 0 8.12 2.5 U 
4 E 8.97 5 0.5 0 9.12 2 P 
4 N1 9.32 5 0 0 9.37 1.5 P 
4 N2 9.52 5 0 0 9.12 1 P 
4 N3 9.18 5 0 0 7.56 3 U 
18 
 
VAS A = VAS Anaesthesia; CAS = Composite Anaesthesia Score; PropB = number of 296 
propofol boli; UES = Undesired Effects Score; VAS R: VAS Recovery; CRS = 297 
Composite Recovery Score; P = promising complex; U = unpromising complex. 298 
 299 
 300 
Discussion 301 
The main finding of this study is that the optimal alfaxalone–dexmedetomidine–302 
butorphanol combination established by applying the optimization method resulted in 303 
reliable, rapid onset, and uneventful anaesthesia in cats undergoing minor surgical 304 
procedures. 305 
The modified version of the optimization method as used in this study was feasible, 306 
applicable to the clinical setting and compatible with the routine of a busy veterinary 307 
hospital.  308 
The rational for using a relatively high number of cats was the premise that, for an 309 
objective and unbiased data collection, the investigator needed to be blind to the 310 
treatments at each step of the search process. This implied the repetition of the good 311 
treatments, so that each complex could be composed of 5 groups. A different study 312 
design, with the investigator responsible for data collection completely unaware of the 313 
study phases, would have allowed the avoidance of such repetition, making the all 314 
process easier and less time consuming.  315 
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None of the cats had complications. However, mild hypertension and bradycardia were 316 
observed in some animals, a finding which limits the use of the anaesthetic protocol to 317 
healthy cats. 318 
Providing a definition of bradycardia and hypertension in anaesthetized cats is 319 
challenging owing to the conflicting results of the currently published work. It was 320 
reported that feline patients have considerably lower heart rates when the measurements 321 
are taken in home environment compared to the hospital, and that normal values for HR 322 
in quiet cats are 132 ± 19.18 Considering that under anaesthesia even lower values could 323 
be regarded as normal, for this trial bradycardia was defined as HR lower than 100.  324 
Regarding the systolic arterial pressure, according to Domanjko and colleagues normal 325 
values range from 100 to 150 mmHg in anaesthetized cats.19 Hence, in the present study 326 
values higher than 150 mmHg were considered indicative of hypertension.  327 
One limitation of the proposed anaesthetic protocol is that the addition of alfaxalone, 328 
which is available on the market only at a concentration of 10 mg/ml, greatly increases 329 
the volume of injectate in comparison to a classical dexmedetomidine-ketamine 330 
combination. This certainly makes the intramuscular injection an unpleasant experience 331 
for feline patients, and implies that two injections are often necessary to split the 332 
volume into two anatomic sites. Additionally, a high volume IM injection carries the 333 
potential for iatrogenic muscular injuries. In the light of these considerations, it was 334 
decided to fix the maximal alfaxalone dose at 2.5 mg/kg (corresponding to a volume of 335 
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0.25 ml/kg). Nevertheless, none of the cats enrolled in the study showed signs of pain at 336 
the injection sites or impairment of the injected limb motor function in the post-337 
anaesthetic period.  338 
One important thing to consider when comparing different anaesthetic treatments is that 339 
the procedures to be performed in the anaesthetized patients should be similar in terms 340 
of duration and degree of nociceptive stimulation. Because of the clinical nature of the 341 
current trial, a standardization of the surgical procedure was not possible. After an 342 
attentive analysis of the caseload of the Institution in which the study was conducted, it 343 
was decided to enroll only cats undergoing one of the two most common minor 344 
procedures. Unarguably, the surgical curettage of a skin wound and the removal of a pin 345 
from a bone may be different in terms of types and intensity of nociceptive stimulation. 346 
However, the even distribution of the types of procedure, and the lack of significant 347 
difference in its duration, between treatments, should have prevented our findings from 348 
being biased.    349 
 350 
Conclusions 351 
The modified optimization method as described by Berenbaum was easy to apply and 352 
allowed to establish a useful drug combination to be used in clinical patients.  353 
Dexmedetomidine-alfaxalone-butorphanol combination, at the doses of 0.014, 2.5 and 354 
0.3 mg/kg, respectively, produces good quality injectable anaesthesia, characterized by 355 
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reliability, rapid onset and lack of complications, in feline patients and can be 356 
recommended for minor surgical procedures. 357 
 358 
Acknowledgements The authors would like to thank Dr. Laura Züger for her fine 359 
contribution to data collection. 360 
 361 
Conflict of interest The authors do not have any potential conflicts of interest to 362 
declare. 363 
 364 
References 365 
1 Ansah OB, Raekallio M and Vainio O. Comparison of three doses of 366 
dexmedetomidine with medetomidine in cats following intramuscular 367 
administration. J vet Pharmacol Therap 1998; 21: 380 - 387. 368 
2 Granholm M, McKusick B, Westerholm F, et al. Evaluation of the clinical 369 
efficacy and safety of dexmedetomidine or medetomidine in cats and their 370 
reversal with atipamezole. Vet Anaesth Analg 2006; 33:214-223. 371 
3 Commiskey S, Fan I, Ho I, et al. Butorphanol: effects of a prototypical 372 
agonist-antagonist analgesic on κ-opioid receptors. J Pharmacol Sci 2005; 373 
98:109 - 116. 374 
22 
 
4 Lascelles B and Robertson S. Use of thermal threshold response to evaluate 375 
the antinociceptive effects of butorphanol in cats. Am J Vet Res 2004; 376 
65:1085 - 1089. 377 
5 Johnson J, Robertson S and Pypendop B. Antinociceptive effects of 378 
butorphanol, buprenorphine, or both, administered intramuscularly in cats. 379 
Am J of Vet Res 2007; 68:699-703. 380 
6 Selmi A, Mendes G, Lins B, et al. Evaluation of the sedative and 381 
cardiorespiratory effects of dexmedetomidine, dexmedetomidine-382 
butorphanol, and dexmedetomidine-ketamine in cats. J Am Vet Med Assoc 383 
2003; 222:37-41. 384 
7 Hanna R, Borchard R and Schmidt S. Pharmacokinetics of ketamine HCl and 385 
metabolite 1 in the cat: a comparison of i.v., i.m., and rectal administration. 386 
J Vet Pharmacol Therap 1988; 11:84-93. 387 
8 Allen DG, Dyson DH, Pascoe PJ, et al. Evaluation of a xylazine-ketamine 388 
hydrochloride combination in the cat. Can J Vet Res 1986; 50:23-26. 389 
9 Akkerdaas LC, Mioch P, Sap R, et al. Cardiopulmonary effects of three 390 
different anaesthesia protocols in cats. Vet Q 2001; 23:182-186. 391 
10 Belda E, Laredo F, Escobar M, et al. Anaesthetic and cardiorespiratory 392 
effects of romifidine/ketamine combinations in cats. Vet Anaesth Analg 2009; 393 
36 299-307. 394 
23 
 
11 Biermann K, Hungerbühler S, Mischke R, et al. Sedative, cardiovascular, 395 
haematologic and biochemical effects of four different drug combinations 396 
administered intramuscularly in cats. Vet Anaesth Analg 2012; 39:137-150. 397 
12 Ko J, Austin B, Barletta M, et al. Evaluation of dexmedetomidine and 398 
ketamine in combination with various opioids as injectable anesthetic 399 
combinations for castration in cats. J Am Vet Med Assoc 2011; 239:1453-400 
1461. 401 
13 Muir W, Lerche P, Wiese A, et al. The cardiorespiratory and anesthetic 402 
effects of clinical and supraclinical doses of alfaxalone in cats. Vet Anaesth 403 
Analg 2009; 36 42-54. 404 
14. Heit M, Schnell M, Whittem T, et al. Safety and efficacy of Alfaxane-CD RTU 405 
administered once to cats subcutaneously at 10 mg/kg. 22nd American 406 
College of Veterinary Internal Medicine (ACVIM) Forum June 2004; 432. 407 
15. Ramoo S, Bradbury L, Anderson G, et al. Sedation of hyperthyroid cats with 408 
subcutaneous administration of a combination of alfaxalone and 409 
butorphanol. Aust Vety J 2013; 91:131-136. 410 
16. Sveticic G, Gentilini A, Eichenberger U, et al. Combinations of morphine with 411 
ketamine for patient-controlled analgesia - a new optimization method. 412 
Anesthesiology 2003; 98:1195 - 1205. 413 
24 
 
17. Berenbaum M. Direct search method in the optimisation of cancer 414 
chemotherapy regimens. Br J Cancer 1990; 61:101-109. 415 
18. Abbot JA. Heart rate and heart rate variability of healthy cats in home and 416 
hospital environments. J Feline Med Surg 2004; 7:195-202. 417 
19. Domanjko Petrič A, Petra Z, Jerneja S, et al. Comparison of high definition 418 
oscillometric and Doppler ultrasonic devices for measuring blood pressure 419 
in anaesthetised cats. J Feline Med Surg 2010; 12:731-737. 420 
 421 
 422 
 423 
 424 
 425 
 426 
 427 
 428 
 429 
 430 
 431 
 432 
 433 
25 
 
Figure legends 434 
Figure 1 435 
Box and whisker plots of duration of the clinical procedure in 120 anaesthetized cats. 436 
Boxes represent the interquartile range (central 50% of values), while the horizontal 437 
lines within the boxes are the medians. The upper and lower whiskers represent the 438 
upper and lower ranges of values, respectively. The dots represent the outliers.  439 
Figure 2 440 
Box and whisker plots of heart rates (beats per minute) of 120 cats undergoing minor 441 
surgical procedures under injectable anaesthesia. Boxes represent the interquartile range 442 
(central 50% of values), while the horizontal lines within the boxes are the medians. The 443 
upper and lower whiskers represent the upper and lower ranges of values, respectively. 444 
The dots represent the outliers.  445 
Figure 3 446 
Box and whisker plots of respiratory rates (breaths per minute) of 120 cats undergoing 447 
minor surgical procedures under injectable anaesthesia. Boxes represent the interquartile 448 
range (central 50% of values), while the horizontal lines within the boxes are the 449 
medians. The upper and lower whiskers represent the upper and lower ranges of values, 450 
respectively. The dots represent the outliers.  451 
Figure 4 452 
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Box and whisker plots of systolic arterial pressures (mmHg) of 120 cats undergoing 453 
minor surgical procedures under injectable anaesthesia. Boxes represent the interquartile 454 
range (central 50% of values), while the horizontal lines within the boxes are the 455 
medians. The upper and lower whiskers represent the upper and lower ranges of values, 456 
respectively. The dots represent the outliers.  457 
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